CITIUS PHARMACEUTICALS INC

CTXRNASDAQ

🏆 #3633 by market capUS Equity

$323.57▲ $4.89 (+1.51%)

🌙 After hours$0.71▼ 99.78%Simulated price

1h—

24h▲ 1.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$20M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for CTXR.

Trading Snapshot

Day Range: $321.08 – $328.03
52-Week Range: $0.47 – $2.19
Volume: $3.17B
Avg Volume: $2.22B
Shares Outstanding: 27.4M
Next Earnings: Sep 12, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $2M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.59
Dividend Yield: —

Why Investors Own CTXR

✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +40.0% YoY

Gross Margin (TTM)

40.4%▲ +3.6% YoY

Operating Income (TTM)

$237,833▲ +40.0% YoY

Free Cash Flow (TTM)

$73,921▲ +40.0% YoY

About CITIUS PHARMACEUTICALS INC

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

🦦